Format

Send to

Choose Destination
PLoS One. 2012;7(5):e37624. doi: 10.1371/journal.pone.0037624. Epub 2012 May 23.

Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype.

Author information

1
Department of Breast Surgery, Breast Cancer Institute, Cancer Hospital, Fudan University, Shanghai, People's Republic of China.

Erratum in

  • PLoS One. 2014;9(7):e102404.

Abstract

BACKGROUND AND AIM:

We investigated the prognostic importance of dickkopf-1(DKK1) and beta-catenin expression in triple negative breast cancers.

METHODS:

The expression of DKK1 and beta-catenin was evaluated in breast cell lines using RT-PCR and western blot. Immunohistochemistry was used to characterize the expression pattern of DKK1 and beta-catenin in 85 triple negative breast cancers and prognostic significance was assessed by Kaplan-Meier analysis and Cox proportional hazards regression modeling.

RESULTS:

The expression of DKK1 was confirmed in hormone-resistant breast cell lines MDA-MB-231, MDA-MB-231-HM and MDA-MB-435. Expression of DKK1 in triple negative breast cancers correlated with cytoplasmic/nuclear beta-catenin (p = 0.000). Elevated expression of DKK1 and cytoplasmic/nuclear beta-catenin in triple negative cancers indicate poor outcome of patients. DKK1 was also a prognostic factor for patients with earlier stage or no lymph node metastasis.

CONCLUSION:

DKK1 together with beta-catenin might be important prognostic factors in triple negative breast carcinoma. DKK1 might be a valuable biomarker in predicting the prognosis of patients with earlier stage or no lymph node metastasis. It is possible that through further understanding of the role of Wnt/beta-catenin pathway activation, beta-catenin would be a potential therapeutic target for the triple negative breast cancer.

PMID:
22649545
PMCID:
PMC3359298
DOI:
10.1371/journal.pone.0037624
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center